SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
zjj970654859
Lv4
1
430 积分
2023-08-26 加入
最近求助
最近应助
互助留言
Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
2小时前
已关闭
Metastatic Ablation in Epidermal Growth Factor Receptor Mutated Oligometastatic Non-Small Cell Lung Cancer—Upfront or Outback After Systemic Tyrosine Kinase Inhibitors?
1天前
已完结
Ablative Radiation Therapy for Oligometastatic EGFR-Mutated Non-small Cell Lung Cancer: Who, Why, When, and How?
1天前
求助中
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
14天前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
14天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
15天前
已完结
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC
18天前
已完结
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
18天前
已完结
Osimertinib in Stage III EGFR -Mutated NSCLC — Game, Set, Match
21天前
已完结
Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
21天前
已完结
没有进行任何应助
找到了【积分已退回】
2小时前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论